Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has shared an update.
Recce Pharmaceuticals Ltd reported progress in its anti-infective portfolio, highlighted by a successful A$12.4 million fundraising and promising results from its study on RECCE® 327 against multidrug-resistant Acinetobacter baumannii. The company received a US$2 million grant from the US Department of Defence for its RECCE® 327 Gel, aimed at treating burn wound infections, and advanced its clinical trials for diabetic foot infections. Additionally, Recce received a significant R&D Tax Incentive rebate, supporting its ongoing research and development efforts.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd is a biotechnology company focused on developing anti-infective drugs. Their primary product, RECCE® 327, targets multidrug-resistant pathogens, with a market focus on addressing significant unmet medical needs in infections such as diabetic foot infections and burn wound infections.
YTD Price Performance: -10.42%
Average Trading Volume: 116,515
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: A$99.7M
Learn more about RCE stock on TipRanks’ Stock Analysis page.